Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10088131 | 0.90 | CASP2 (0.56) | CASP2ACE2NAAALTA4HFAAH | |
| SCHEMBL12666301 | 0.89 | CASP2 (0.59) | CASP2ACE2NAAAMEN1KMT2A | |
| SCHEMBL47703 | 0.89 | CASP2 (0.59) | CASP2ACE2NAAAMEN1KMT2A | |
| SCHEMBL12413859 | 0.86 | CYP1A2 (0.52) | CASP2ACE2NAAALTA4HMEN1 | |
| SCHEMBL20900404 | 0.86 | MEN1 (0.63) | CASP2ACE2NAAALTA4HMEN1 | |
| SCHEMBL14217283 | 0.86 | MEN1 (0.63) | CASP2ACE2NAAALTA4HMEN1 | |
| SCHEMBL20055001 | 0.84 | CASP2 (0.52) | CASP2ACE2NAAAFAAHALDH1A1 | |
| SCHEMBL17123487 | 0.84 | CASP2 (0.66) | CASP2NAAAMEN1KMT2AFAAH | |
| SCHEMBL16638262 | 0.83 | ALDH1A1 (0.44) | CASP2ACE2NAAALTA4HMEN1 | |
| SCHEMBL16944361 | 0.83 | EPHX2 (0.54) | CASP2LTA4HFAAHCYP1A2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695226-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-07-04 | — | — | US | disclosed |